Pentoxifylline Extended-Release Tablets 400 mg

Similar documents
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Clinical Study Synopsis for Public Disclosure

Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure

Application of IVIVCs in Formulation Development Douglas F Smith


Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

Public Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC

Public Assessment Report. Scientific discussion. Leflunomide Apotex 10 mg and 20 mg, tablets. (leflunomide) NL/H/2548/ /DC

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Bioequivalence of MR Products. AGAH Conference on the New European Modified Release Guideline Bonn, June 15 th, 2015

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects

Final Report (Amendment 1) April 11, 2006 Page 4 of 50

Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen

Selected Properties of Daclatasvir

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

SCIENTIFIC DISCUSSION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Jieon Lee 1, AnHye Kim 1, Kyung-Sang Yu 1, Jae-Yong Chung 2, Sung-Vin Yim 3 and Bo-Hyung Kim 3 * 1 ORIGINAL ARTICLE

Article by Venkatesh Pandi Clinical Research, Texila American University, India Abstract

Public Assessment Report. Scientific discussion. Sertraline Apotex 50 mg and 100 mg, film-coated tablets (sertraline hydrochloride)

Annex I. List of the names, pharmaceutical form, strengths of the medicinal product, route of administration, applicants in the Member States

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Section 5.2: Pharmacokinetic properties

Patients with renal impairment: Adjust dose based on creatinine clearance. (2.3) DOSAGE FORMS AND STRENGTHS

Section 3.F and Section 6 Human Pharmacokinetics and Bioavailability

mg per day, given in divided doses twice daily (2.2)

APO-ACAMPROSATE ENTERIC COATED TABLETS

Product: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use

Pharmacology of generics. Dario Cattaneo Unit of Clinical Pharmacology Luigi Sacco University Hospital, Milano, ITALY

CHOLESTAGEL 625 mg Genzyme

Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers

CO-ADMINISTRATION WITH GRAZOPREVIR AND ELBASVIR HAS NO EFFECT ON PRAVASTATIN EXPOSURE BUT INCREASES ROSUVASTATIN EXPOSURE IN HEALTHY SUBJECTS

Photo (compulsory) Columbia University Medical Center, New York, NY 2. University of Southern California, Keck School of Medicine, Los Angeles, CA 3

Delivery systems for nutraceuticals Enhanced bioavailability and improved functionality for lipophilic nutrients

PUBLIC ASSESSMENT REPORT Scientific Discussion

Public Assessment Report Scientific discussion. Flucloxacillin Orion (flucloxacillin sodium) SE/H/981/03/DC

BIOEQUIVALENCE STUDY OF TOPIRAMATE

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

EMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.

Pharmacokinetics of Ketamine and Norketamine After Oral Administration of a Liquid Formulation of Ketamine

Redefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs

T Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz

Multiple IV Bolus Dose Administration

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Session 1 : Orally Administered Modified Release Products

Gemigliptin Tartrate Sesquihydrate Tablets 50mg

SCIENTIFIC DISCUSSION

Pharmacokinetics in Drug Screening

PRODUCT MONOGRAPH APO-DILTIAZ. Diltiazem HCI Tablets USP 30 and 60 mg Antianginal Agent

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION. Efavirenz

SUMMARY OF PRODUCT CHARACTERISTICS

Public Assessment Report Scientific discussion. Ciprofloxacin Pfizer (Ciprofloxacin hydrochloride) SE/H/803/01-03/DC

Decentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC

SCIENTIFIC DISCUSSION

Public Assessment Report. Scientific discussion. Diliban Retard Tramadol/Paracetamol IS/H/0168/001/DC. Date:

Public Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC

CHMP ASSESSMENT REPORT FOR. Raloxifene Teva. International Nonproprietary Name: raloxifene Procedure No. EMEA/H/C/001075

SCIENTIFIC DISCUSSION

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Public Assessment Report Scientific discussion. Quetiapin Orion (quetiapine fumarate) SE/H/1115/01-04/DC

Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.

SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:

Study Centers: This study was conducted in 2 centers in Italy.

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Influence of mycotoxin binders on the oral bioavailability of doxycycline in pigs

Bioequivalence Study of Sildenafil 20 mg Tablets in Healthy Thai Male Volunteers

London Medicines Information Service

Public Assessment Report. Scientific discussion

Ju-Hee Ryu, Sang-Jun Choi, Myung-Jae Lee, Jin-Sung Lee, Jong-Min Kang, Sung-Kwon Tak, Ji-Hyung Seo and Kyung-Tae Lee

CONTRAINDICATIONS None.

Soma)con PHARMACEUTICALS

Public Assessment Report Scientific discussion. Losartan/Hydrochlorothiazide Bluefish (losartan/hydrochlorothiazide) SE/H/780/01-02/DC

Natazia safely and effectively. See full prescribing information

Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085

SCIENTIFIC DISCUSSION

Clinical Study Synopsis for Public Disclosure

Presentation #: OP221

FREEDOM OF INFORMATION SUMMARY

Revised: 11/2017 FULL PRESCRIBING INFORMATION: CONTENTS* 10 OVERDOSAGE 1 INDICATIONS AND USAGE 11 DESCRIPTION

Ciprofloxacin Bluefish (Ciprofloxacin hydrochloride)

Transcription:

Pentoxifylline Extended-Release Tablets 4 mg COMPARATIVE BIOAVAILABILITY STUDIES APOTEX CORP.

Product: Pentoxifylline Extended-Release Tablets Approval Date: June 9, 1999 Indication: Description: treatment of patients with chronic occlusive peripheral vascular disease of the extremities white, oval, unscored, film-coated tablets, imprinted with "APO 33" on one side and plain on the other side COMPARATIVE BIOAVAILABILITY STUDIES OF APOTEX CORP. PENTOXIFYLLINE EXTENDED-RELEASE AND TRENTAL 4 mg TABLETS Study Design: Fasting Biostudy: Food Effect Biostudy: Steady State Biostudy: Standard 2-way cross-over bioavailability study Standard 3-way cross-over bioavailability study Standard 2-way cross-over steady state study Subjects: Normal human volunteers Normal human volunteers Normal human volunteers Number: 37 Number: 16 Number: 24 Mean Age: 28.3 years Mean Age: 27.8 years Mean Age: 32.3 years Mean Weight: 164.4 lbs Mean Weight: 16.4 lbs Mean Weight: 174.5 lbs Dose Administered: 4 mg (1 tablet) 4 mg (1 tablet) 4 mg (1 tablet) at, 8, 16, 24, 32, 4, 48, 56, 64, 72, 8, 88, and 96 hours Sampling At:,.33,.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 1, 12, 15, 18, 21, and 24 hours,.33,.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 1, 12, 15, 18, 21, and 24 hours Assay Method: LC/MS/MS LC/MS/MS LC/MS/MS Washout Time: 1 week 1 week 1 week, 24, 48, 72, 96, 96.25, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 1, 11, 12, 13, 14, 16, 18, 111, 114, and 12 hours

FASTING BIOSTUDY Pentoxifylline 9% Confidence Intervals * AUC -inf (ng hr / ml) 837.62 (36.) 84.31 (39.8).85-1.6 AUC -T (ng hr / ml) 665.34 (45.9) 681.72 (44.2).92-1.7 Cmax (ng / ml) 17.95 (47.8) 17.65 (42.3).9-1.11 Pentoxifylline 9% Confidence Intervals * AUC -inf (ng hr / ml) 3555.5 (37.9) 3518.99 (4.5).95-1.7 AUC -T (ng hr / ml) 3183.2 (38.1) 332.6 (42.4).93-1.6 Cmax (ng / ml) 393.8 (4.8) 41.5 (44.1).92-1.11 Pentoxifylline 9% Confidence Intervals * AUC -inf (ng hr / ml) 6338.4 (27.2) 6258.22 (27.7).97-1.13 AUC -T (ng hr / ml) 631.5 (23.6) 5913.49 (27.8).98-1.1 Cmax (ng / ml) 789.92 (25.9) 74.62 (31.4) 1.2-1.15 1 9 8 7 6 5 4 3 2 1 4 8 12 16 2 24 4 35 3 25 2 15 1 5 4 8 12 16 2 24 8 7 6 5 4 3 2 1 4 8 12 16 2 24

FOOD EFFECT BIOSTUDY AUC -T (ng hr/ml) 772.1 (74.2) 782.64 (72.1) 692.53 (72.8) 1. Cmax (ng/ml) 143.94 (77.8) 183.5 (72.) 128.59 (14.2).86 AUC -T (ng hr/ml) 3386.68 (69.1) 331.61 (73.1) 3249.98 (73.9) 1.3 Cmax (ng/ml) 53.91 (71.8) 594.88 (71.2) 446.6 (87.3).87 AUC -T (ng hr/ml) 6288.69 (23.7) 5934.6 (31.1) 5831.56 (28.) 1.1 Cmax (ng/ml) 933.38 (32.6) 998.44 (36.7) 833.31 (33.1).93 12 1 8 6 4 2 4 8 12 16 2 24 45 9 4 35 3 25 2 15 1 8 7 6 5 4 3 2 5 1 4 8 12 16 2 24 4 8 12 16 2 24

STEADY STATE BIOSTUDY 9% Confidence Intervals * AUC 96-14 (ng hr/ml) 62.7 (41.8) 593.15 (42.7).93-1.9 Cmax (ng/ml) 139.83 (51.5) 145.81 (55.3).82-1.11 9% Confidence Intervals * AUC 94-14 (ng hr/ml) 2494.33 (35.1) 2568.37 (33.7).88-1.4 Cmax (ng/ml) 462.92 (38.2) 471.58 (33.2).86-1.6 9% Confidence Intervals * AUC 96-14 (ng hr/ml) 6122.83 (27.7) 6538.54 (23.5).83-1.1 Cmax (ng/ml) 1178.71 (28.3) 1249. (22.).82-1.2 14 12 1 8 6 4 2 96 97 98 99 1 11 12 13 14 5 45 4 35 3 25 2 15 1 5 96 97 98 99 1 11 12 13 14 14 12 1 8 6 4 2 96 97 98 99 1 11 12 13 14